In re U.S. Bioscience Securities Litigation

155 F.R.D. 116, 1994 U.S. Dist. LEXIS 7171, 1994 WL 232045
CourtDistrict Court, E.D. Pennsylvania
DecidedMay 27, 1994
DocketCiv. A. No. 92-678
StatusPublished
Cited by26 cases

This text of 155 F.R.D. 116 (In re U.S. Bioscience Securities Litigation) is published on Counsel Stack Legal Research, covering District Court, E.D. Pennsylvania primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
In re U.S. Bioscience Securities Litigation, 155 F.R.D. 116, 1994 U.S. Dist. LEXIS 7171, 1994 WL 232045 (E.D. Pa. 1994).

Opinion

MEMORANDUM

DALZELL, District Judge.

On April 6, 1994, we approved the settlement of this consolidated class action. The settlement provided for the payment of $5,250,000 in cash, plus interest from January 31, 1994, and $10,000,000 in marketable securities, consisting of units composed of U.S. Bioscience common stock and warrants.1

Beside approving the settlement, we were also asked to approve requests for attorneys’ fees and cost reimbursements, as well as to make “incentive awards” to thirty-five class representatives. We shall consider these fee requests and “incentive awards” separately.

Attorneys’ Fees

On the same day as we approved the settlement, we appointed the Honorable Arlin M. Adams as Special Master to prepare a Report and Recommendation on the appropriate fee percentage to award plaintiffs’ counsel for their labors in this litigation. No less than thirty-four firms applied for counsel fees from the class settlement, as well as three other firms who sought fees as part of the resolution of the derivative claims asserted in the consolidated amended complaint.2

In appointing Judge Adams as Special Master, we directed him to be guided by the recommendations set forth in the October 8, 1985 report of the Third Circuit Task Force, “Court Awarded Attorney Fees,” 108 F.R.D. 237 (the “Task Force Report”). Notwithstanding the eminence of its parentage,3 we have found no decision of the Third Circuit formally embracing the Task Force Re[118]*118port.4 We therefore will briefly explain why we have chosen to apply the Task Force Report’s recommendations here.

The Task Force Report concluded that in “common fund” or, as it refers to it, “fund-in-court” eases such as this class action, a percentage of recovery fee is preferable to a “lodestar” approach commonly employed in fee-shifting cases.5 The “lodestar” approach stems from the Third Circuit’s seminal decisions in Lindy Bros. Builders v. American Radiator & Standard Sanitary Corp., 487 F.2d 161 (3d Cir.1973) (“Lindy I”), appeal following remand) 540 F.2d 102 (3d Cir.1976) (“Lindy II ”). We agree that the Task Force Report’s preference for a percentage of recovery approach makes sense in this common fund case.

As witnessed here, where a sudden and significant loss occurs to the price of publicly traded common stock, there is an almost instantaneous response from a skilled and highly entrepreneurial bar.6 In this case, within a week of the FDA announcement that halved Bioscience’s stock price, over two dozen suits were filed. Though we early consolidated these suits and plaintiffs ultimately filed an omnibus Consolidated Amended Complaint, no less than thirty-four firms appeared for thirty-five plaintiffs in these actions. There was, however, only one class certified.7 From the point of view of the class, only the result matters — the number of law firms does not. By adopting a percentage of recovery fee, the number of plaintiffs’ lawyers involved becomes irrelevant.

Almost as important, under a percentage regime the class’s champions do not have the disincentive to early settlement that we regard as an inevitable and highly undesirable consequence of the lodestar approach. The Task Force Report’s wisdom thus doubly applies well here.8

As the Task Force Report observed, when a lawyer in a common fund case secures a recovery for a class, and then seeks compensation from the same fund, the lawyer’s role changes “from one of a fiduciary for the clients to that of a claimant against the fund created for the clients’ benefit.” 108 F.R.D. at 255. Thus, in such a circumstance, “[t]he perspective of the judge also changes because the court now must monitor the disbursement of the fund and act as a fiduciary for those who are supposed to benefit from it____” Id. The Task Force Report therefore recommended that, as soon as possible, the court should appoint a negotiator “who will vigorously represent the interests of the beneficiaries [i.e., the class],” and who will “behave in exactly the same fashion as would any other attorney in a comparable situation” in negotiating “in an open and appropriately arm’s length manner” a reasonable compensation plan. 108 F.R.D. at 256-57.

While the Task Force Report’s recommendation unquestionably will produce the kind of fee agreement refined by the rigors of the legal marketplace, at the beginning of this hotly-contested litigation that option did not seem to us to be available. In order to achieve the “appropriately arm’s length man[119]*119ner” that a sophisticated client would bring to a negotiation with a prospective lawyer, it seemed to us that the negotiator necessarily would have to be paid for his services. At least here, it was not realistic or reasonable to ask the defendants to fund any part of the cost of such a negotiator in a litigation in which they believed no claims would survive their motions under Fed.R.Civ.P. 12(b)(6). See In re U.S. Bioscience Securities Litigation, 806 F.Supp. 1197 (E.D.Pa.1992). This reality meant that only the plaintiffs’ lawyers could provide the funds to pay for such a negotiator. A plaintiffs’-lawyer-paid patron seemed to us to present the kind of conflict of interest that would be intolerable in a judicial setting, and one that fair-minded people could reasonably conclude would not result in a fee arrangement that was achieved in an “appropriately arm’s length manner”.9

For these reasons, we appointed Judge Adams after the settlement fund had been created “to determine what contingent fee arrangement would likely be negotiated in the market in this District for legal services in business litigation similar to this Consolidated Action____” On May 23, 1994, Judge Adams filed his forty-nine page Report and Recommendation. By letter the next day, plaintiffs’ co-lead counsel advised us that they had no objection to the Report and Recommendation.

In preparing his Report, the Special Master reviewed a number of affidavits and other documents detailing the fee percentages in other complex litigations. As Judge Adams points out in his Report, each of the other cases proffered differ in material respects from the one before the Court now. Far from being unhelpful, however,

The Special Master concludes that this set of affidavits and documents is useful not so much in suggesting a specific fee percentage for this case, but rather in underscoring two fundamental aspects of the fee negotiation process: first, that the client’s needs and concerns are generally factored into any contingency fee agreement ..., and second, that many contingency fee agreements are, as the Task Force Report suggests, “custom-tailor[ed]” to the facts and circumstances, including the extent of the services actually provided by the attorneys.

Report and Recommendation at 24, quoting the Task Force Report at 108 F.R.D. at 256.

After carefully analyzing the particulars of this litigation, the Special Master concluded as follows with respect to the fee percentage:

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Hashw v. Department Stores National Bank
182 F. Supp. 3d 935 (D. Minnesota, 2016)
Good v. Nationwide Credit, Inc.
314 F.R.D. 141 (E.D. Pennsylvania, 2016)
Medical Mutual of Ohio v. SmithKline Beecham Corp.
291 F.R.D. 93 (E.D. Pennsylvania, 2013)
In re Flonase Antitrust Litigation
951 F. Supp. 2d 739 (E.D. Pennsylvania, 2013)
Stagi v. National Railroad Passenger Corp.
880 F. Supp. 2d 564 (E.D. Pennsylvania, 2012)
McDonough v. Toys "R" Us, Inc.
834 F. Supp. 2d 329 (E.D. Pennsylvania, 2011)
Perry v. Fleetboston Financial Corp.
229 F.R.D. 105 (E.D. Pennsylvania, 2005)
Eldridge v. Provident Companies, Inc.
18 Mass. L. Rptr. 678 (Massachusetts Superior Court, 2005)
Milkman v. American Travellers Life Insurance
61 Pa. D. & C.4th 502 (Philadelphia County Court of Common Pleas, 2002)
Carrabba v. Randalls Food Markets, Inc.
191 F. Supp. 2d 815 (N.D. Texas, 2002)
Laborers Local 1298 Annuity Fund Ex Rel. Rite Aid Corp. v. Grass
146 F. Supp. 2d 706 (E.D. Pennsylvania, 2001)
Fry v. Hayt, Hayt & Landau
198 F.R.D. 461 (E.D. Pennsylvania, 2000)
Karcich v. Stuart
194 F.R.D. 166 (E.D. Pennsylvania, 2000)
In Re Horizon/CMS Healthcare Corp. Securities Litigation
3 F. Supp. 2d 1208 (D. New Mexico, 1998)
In re Southern Ohio Correctional Facility
175 F.R.D. 270 (S.D. Ohio, 1997)
Seidman v. American Mobile Systems
965 F. Supp. 612 (E.D. Pennsylvania, 1997)
In Re Chambers Development Securities Litigation
912 F. Supp. 822 (W.D. Pennsylvania, 1995)

Cite This Page — Counsel Stack

Bluebook (online)
155 F.R.D. 116, 1994 U.S. Dist. LEXIS 7171, 1994 WL 232045, Counsel Stack Legal Research, https://law.counselstack.com/opinion/in-re-us-bioscience-securities-litigation-paed-1994.